全文获取类型
收费全文 | 721篇 |
免费 | 44篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 4篇 |
妇产科学 | 17篇 |
基础医学 | 94篇 |
口腔科学 | 16篇 |
临床医学 | 50篇 |
内科学 | 178篇 |
皮肤病学 | 22篇 |
神经病学 | 37篇 |
特种医学 | 38篇 |
外科学 | 84篇 |
综合类 | 3篇 |
预防医学 | 16篇 |
眼科学 | 9篇 |
药学 | 70篇 |
中国医学 | 1篇 |
肿瘤学 | 123篇 |
出版年
2023年 | 3篇 |
2022年 | 10篇 |
2021年 | 28篇 |
2020年 | 14篇 |
2019年 | 17篇 |
2018年 | 29篇 |
2017年 | 28篇 |
2016年 | 28篇 |
2015年 | 21篇 |
2014年 | 32篇 |
2013年 | 39篇 |
2012年 | 53篇 |
2011年 | 65篇 |
2010年 | 34篇 |
2009年 | 25篇 |
2008年 | 45篇 |
2007年 | 52篇 |
2006年 | 42篇 |
2005年 | 38篇 |
2004年 | 35篇 |
2003年 | 36篇 |
2002年 | 20篇 |
2001年 | 7篇 |
2000年 | 13篇 |
1999年 | 11篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 4篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1984年 | 2篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1975年 | 5篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1971年 | 4篇 |
1967年 | 1篇 |
1966年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有767条查询结果,搜索用时 15 毫秒
1.
Polyglucosan bodies (PGB) in the central nervous system of an old male fox, Vulpes vulpes japonica, without neurological signs were examined by light and electron microscopy, lectin histochemistry and immunohistochemistry. Fox PGB were round, slightly-basophilic and PAS-positive structures. Most of the bodies were situated free in the neuropil. Electron microscopically, fox PGB were composed mainly of branching filaments and electron-dense material. Lectin histochemistry revealed that fox PGB contained mannose and galactose in addition to glucose. Fox PGB were immunoreactive for monoclonal antibodies raised against human polyglucosan. These findings indicate that fox PGB are similar to feline ones. 相似文献
2.
Wakana Goto Hidehiro Oku Takashi Okuno Tetsuya Sugiyama Tsunehiko Ikeda 《Journal of ocular pharmacology and therapeutics》2003,19(1):63-73
We investigated whether topical instillation of an alpha(1)-adrenergic blocker would improve an insufficient blood supply in the optic nerve head (ONH) and visual function, in rabbits. The effect of systemic NOS inhibition on visual-evoked potentials (VEPs) and hemodynamics in ONH were determined. VEPs were recorded before and every 15 min during a 120-min observation period after an intravenous injection of 50 mg/kg N(G)-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase (NOS) inhibitor. Capillary blood flow in ONH was evaluated by the laser speckle method throughout the same period. Then, we investigated the effect of topical instillation of a recently developed alpha(1) adrenergic blocker, bunazosin hydrochloride (0.01%), 60 min prior to the intravenous L-NAME (50 mg/kg) on the changes by NOS inhibition. The VEP amplitudes were reduced by L-NAME (10, 20, and 50 mg/kg) in a dose-dependent manner, while the VEP implicit time was unchanged, and no significant changes were detected in the electroretinogram. The reductions in ONH capillary blood flow and VEP amplitudes caused by L-NAME (50 mg/kg) were significantly suppressed by an instillation of bunazosin hydrochloride. These results indicate that blocking alpha(1)-adrenergic receptors may ameliorate the impairments in blood flow and retinal function caused by NOS inhibition. The enhancement of basal vascular tone due to deprivation of continuous NO production may be diminished by this alpha(1)-adrenergic blocker. 相似文献
3.
Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia 总被引:3,自引:0,他引:3
Taketomi T Yoshiga D Taniguchi K Kobayashi T Nonami A Kato R Sasaki M Sasaki A Ishibashi H Moriyama M Nakamura K Nishimura J Yoshimura A 《Nature neuroscience》2005,8(7):855-857
We report here that loss of the Sprouty2 gene (also known as Spry2) in mice resulted in enteric nerve hyperplasia, which led to esophageal achalasia and intestinal pseudo-obstruction. Glial cell line-derived neurotrophic factor (GDNF) induced hyperactivation of ERK and Akt in enteric nerve cells. Anti-GDNF antibody administration corrected nerve hyperplasia in Sprouty2-deficient mice. We show Sprouty2 to be a negative regulator of GDNF for the neonatal development or survival of enteric nerve cells. 相似文献
4.
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839) 总被引:7,自引:0,他引:7
Kakiuchi S Daigo Y Ishikawa N Furukawa C Tsunoda T Yano S Nakagawa K Tsuruo T Kohno N Fukuoka M Sone S Nakamura Y 《Human molecular genetics》2004,13(24):3029-3043
Gefitinib (Iressa, ZD1839), an inhibitor of epidermal growth factor receptor-tyrosine kinase, has shown potent anti-tumor effects and improved symptoms and quality-of-life of a subset of patients with advanced non-small cell lung cancer (NSCLC). However, a large portion of the patients showed no effect to this agent. To establish a method to predict the response of NSCLC patients to gefitinib, we used a genome-wide cDNA microarray to analyze 33 biopsy samples of advanced NSCLC from patients who had been treated with an identical protocol of second to seventh line gefitinib monotherapy. We identified 51 genes whose expression differed significantly between seven responders and 10 non-responders to the drug. We selected the 12 genes that showed the most significant differences to establish a numerical scoring system (GRS, gefitinib response score), for predicting response to gefitinib treatment. The GRS system clearly separated the two groups without any overlap, and accurately predicted responses to the drug in 16 additional NSCLC cases. The system was further validated by the semi-quantitative RT-PCR, immunohistochemistry and ELISA for serological test. Moreover, we proved that the anti-apoptotic activity of amphiregulin, a protein that was significantly over-expressed in non-responders but undetectable in responders, leads to resistance of NSCLC cells to gefitinib in vitro. Our results suggested that sensitivity of a given NSCLC to gefitinib can be predicted according to expression levels of a defined set of genes that may biologically affect drug sensitivity and survival of lung cancer cells. Our scoring system might eventually lead to achievement of personalized therapy for NSCLC patients. 相似文献
5.
Gene mapping of SEZ group genes and determination of pentylenetetrazol susceptible quantitative trait loci in the mouse chromosome 总被引:1,自引:0,他引:1
Wakana S Sugaya E Naramoto F Yokote N Maruyama C Jin W Ohguchi H Tsuda T Sugaya A Kajiwara K 《Brain research》2000,857(1-2):286-290
Gene mapping of the newly discovered SEZ genes (seizure-related genes) in the mouse was performed by linkage analysis. SEZ6 was on chromosome 11, SEZ12 on chromosome 16, SEZ15 on chromosome 3 and SEZ17 (PTZ17) on chromosome 18. The mouse chromosomal locus related to high susceptibility to pentylenetetrazol (PTZ) was also determined by linkage analysis using the recombinant inbred mouse, BXD (C57BLxDBA). A significant level of PTZ susceptibility was found on chromosome 2. Chromosomal loci of the newly discovered SEZ genes were not coincident with the significant chromosomal loci to PTZ susceptibility. Since epilepsy is assumed to be a disease syndrome which is probably manifested by abnormal expression of multifocal genes, determination of the role of each chromosomal locus in the provocation of seizure activity is important. 相似文献
6.
Daigo Murata Yoshio Endo Tohru Obata Kazuki Sakamoto Yasuhiro Syouji Masakazu Kadohira Akira Matsuda Takuma Sasaki 《Drug metabolism and disposition》2004,32(10):1178-1182
The antitumor 3'-ethynyl nucleosides, 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine (ECyd) and 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine (EUrd), are potent inhibitors of RNA polymerases and show excellent antitumor activity against various human solid tumors in xenograft models. ECyd is being investigated in phase I clinical trials as a novel anticancer drug possessing a unique antitumor action. ECyd and EUrd require the activity of uridine/cytidine kinase (UCK) to produce the corresponding active metabolite. The UCK family consists of two members, UCK1 and UCK2, and both UCKs are expressed in many tumor cells. It was unclear, however, whether UCK1 or UCK2 is responsible for the phosphorylation of the 3'-ethynyl nucleosides. We therefore established cell lines that are highly resistant to the 3'-ethynyl nucleosides from human fibrosarcoma HT-1080 and gastric carcinoma NUGC-3. All the resistant cell lines showed a high cross-resistance to ECyd and EUrd. As a result of cDNA sequence analysis, we found that UCK2 mRNA expressed in EUrd-resistant HT-1080 cells has a 98-base pair deletion of exon 5, whereas EUrd-resistant NUGC-3 cells were harboring the point mutation at nucleotide position 484 (C to T) within exon 4 of UCK2 mRNA. This mutation was confirmed by genome sequence analysis of the UCK2 gene. Moreover, the expression of UCK2 protein was decreased in these resistant cells. In contrast, no mutation in the mRNA or differences in protein expression levels of UCK1 were shown in the EUrd-resistant HT-1080 and NUGC-3 cells. These results suggest that UCK2 is responsible for the phosphorylation and activation of the antitumor 3'-ethynyl nucleosides. 相似文献
7.
8.
9.
Keiko Toyohara Daigo Yagishita Yoshimichi Kudo Tomomi Nishimura Daiji Takeuchi Yasuko Tomizawa Morio Shoda 《Pacing and clinical electrophysiology : PACE》2021,44(1):181-184
A 42‐year‐old woman with tricuspid atresia who underwent a Fontan surgery (atrio‐pulmonary connection) was admitted to our hospital due to symptomatic ventricular tachycardia (VT). A defibrillation lead was implanted in a distal site of a coronary vein since there was no usual entry to the ventricle. Ventricular pacing was impossible due to the high threshold, however, good sensing was obtained. Three years later, she felt palpitations and a subsequent shock therapy while climbing stairs. The cardioverter data showed that an appropriate cardioversion therapy successfully converted VT to normal rhythm. 相似文献
10.
Eisuke Suganuma Hideaki Sakata Nodoka Adachi Satoshi Asanuma Mihoko Furuichi Yoji Uejima Satoshi Sato Tomoya Abe Daigo Matsumoto Ryohei Takahashi Sachi Yamamoto Yutaka Kawano Takashi Arai Tsutomu Oh-ishi 《Journal of infection and chemotherapy》2021,27(2):185-191
ObjectivesValganciclovir (VGCV) has been shown to improve sensorineural hearing loss (SNHL) and neurological outcomes in patients with neonatal symptomatic congenital cytomegalovirus (cCMV) infection. However, reports on the pharmacokinetics, efficacy and safety of oral VGCV are limited. The aim of this study is to evaluate the pharmacokinetics of VGCV for use in the treatment of cCMV.MethodsThis was a single-center, retrospective observational study conducted at Saitama Children's Medical Center in Japan between 2012 and 2017. CMV DNA copy number, maximum plasma VGCV concentration (Cmax), and adverse events (ADEs) during treatment were evaluated.ResultsA total of 26 patients with cCMV who received VGCV were included in this study. The median age at VGCV initiation was 9.5 months (range 0–46). Twenty-one patients (81%) had SNHL at baseline. Of these, five patients (19%) presented with improved SNHL, and none experienced worsened SNHL during treatment. The mean VGCV Cmax was 3.5 μg/mL (range 2–5.3), with no significant variation among individual values, and the values were maintained during treatment. Furthermore, there were no correlations between the Cmax values and age, sex, SNHL improvement or ADEs. Neutropenia (<1000/mm3) was observed in six patients (23%); however, no serious ADEs occurred.ConclusionsVGCV prevented the progression of SNHL without serious ADEs due to its stable pharmacokinetics. This study provides safety and tolerability of VGCV for the treatment of cCMV patients. 相似文献